Assessment of the Relevance of a Medico-social Care of Elderly Patients, in Relay Between Hospital and Home: Experimentation of TEMPORARY HERBERGEMENT in Retirement Home " EHPAD " in Seine-et-Marne Department (HT77)

February 2, 2023 updated by: Gérond'if
The main objective is to study the impact of Temporary Hebergement (TH), as a medico-social care link between hospital and home, on the length of hospitalization in the referral services.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Terminated

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Detailed Description

It's a non-interventional, multi-centre study.

The request for Temporary Hebergement must be made by the principal investigator or on the recommendation of the other doctors in the co-investigator department at least 48 hours before the discharge from hospital. The EHPAD (Retirement Home) coordinating physician and/or nurse coordinator and the social worker plan the hospitalization release for Temporary Accommodation admission. The social worker must validate with the doctors the feasibility and coherence of the project of return to home, and write a summary attached to the admission file (social report) which will be used in the final analysis of the patients' return-to-home projects included in the study.

The hospital discharge for admission to HT is made with the agreement of the hospital doctor and the host EHPAD (Retirement home). A "check-list" is established to complete the patient's chart.

Upon admission and management of the patient in Temporary Hebergement , he will be followed by his treating physician. If necessary, the on-call doctor of the department that referred the patient may be contacted in case of hospital-applicant care. A mid-term review will be planned by the EHPAD (Retirement home social) worker to anticipate situations at risk of exit blockage at Day 30. The patient will be able to benefit from physiotherapy and speech therapy on prescription by liberal professionals working in the EHPAD, as well as occupational therapy and psychomotricity on the prescription of the coordinating physician during the development of the accompanying project. In addition, the Temporary Hebergement beneficiary will be able to participate in all the social activities of the residence, according to his wishes.

The following data: Quality of Life Questionnaire for Patients (Nottingham Scale) and Caregivers (SF-36 Scale), Caregiver Helper Questionnaire for Home Patients, Caregiver Burden Scale (Zarit) , ADL and IADL scales, EHPAD Patient and Caregiver Perception Questionnaire, Study Acceptability Questionnaire for Included Topics, Patient Comorbidity Evaluation Scale (Charlson) and Socio-Dataeconomic) are collected retrospectively, at Day 0 (inclusion), at Day 15, Day 30, Day 90 and Day 180 which corresponds to the end of the follow-up of patients provided for in the protocol

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
9

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • France
    • Ile-de-France
      • Paris, Ile-de-France, France, 75013
        • Geriatric department , Broca Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

60 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients receiving funded beds for "temporary accommodation" within EHPAD (Retirement Hom) recruiters.

Description

Inclusion Criteria:

  • Patient verbally expressing his non-opposition to participation in the study and documented in the medical record by the physician
  • Hospitalized in hospitals selected as recruiting centers
  • Whose condition is considered compatible by the clinician with discharge from the hospital (stabilized clinical condition)
  • Resident, before hospitalization, in the department of Seine-et-Marne
  • Presenting a defined and feasible return home project
  • whose social situation does not allow an immediate return to the home on discharge from hospital

Exclusion Criteria:

  • Patient expressing his opposition to participation in the study
  • Acute condition not stabilized as per physician's medical opinion
  • Requiring non-insured care by the host EHPAD, namely intravenous infusions, peritoneal dialysis, palliative care, etc.
  • MMS score below 18
  • Exhibiting behavioural disorders with major aggression and walking

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Retrospective

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
The main criterion used is the average length of stay (DMS) found at the end of the study, compared to the MSD for the two previous years in the services addressed.
Time Frame: 180 days
180 days

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Time Frame
Assessment of commorbidity risk according Charlson score
Time Frame: Inclusion , 2days
Inclusion , 2days
Assessment of teh degree of autonomy according AGGIR score
Time Frame: 180 days
180 days
Assessment of quality of life according "Nottingham health profile" scale
Time Frame: 180 days
180 days
Assessment of health-related quality of life according SF-36 (Medical outcome study Short-Form health survey-36 items)
Time Frame: 180 days
180 days
Assessment of the emotional, physical and financial burden on a caregiver according Zarit burden scale
Time Frame: 180 days
180 days
Assessment of the degree of patient dependence according "Index of Independence in Activities of Daily Living" KATZ scale
Time Frame: 180 days
180 days
Assessment of patient's level of dependence through an appreciation of instrumental activities of daily living according Lawton scale
Time Frame: 180 days
180 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Gérond'if

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 17, 2020

Primary Completion (ACTUAL)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 30, 2021

Study Completion (ACTUAL)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 30, 2021

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 7, 2019

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 7, 2019

First Posted (ACTUAL)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 10, 2019

Study Record Updates

Last Update Posted (ACTUAL)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
February 6, 2023

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 2, 2023

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
February 1, 2023

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 2019-A01189-48

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings